Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone

Clinical Pharmacology and Therapeutics

Volumn 63, Issue 6, 1998, Pages 640-645

  Lamberg, Tommi S ^a,b   Kivistö, Kari T ^a,b   Neuvonen, Pertti J ^a,b  

^a Helsinki University Central Hospital ^*

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; DILTIAZEM; PLACEBO; VERAPAMIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CRITICAL FLICKER FUSION; DOSE TIME EFFECT RELATION; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; BUSPIRONE; CALCIUM CHANNEL BLOCKERS; CROSS-OVER STUDIES; DILTIAZEM; FEMALE; HUMANS; MALE; REFERENCE VALUES; SEROTONIN AGONISTS; VERAPAMIL;

EID: 0031844932     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90087-X     Document Type: Article

References (22)

1. Goa KL, Ward A. Buspirone: a preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 1986;32:114-29.
2. Bond AJ, Lader MH. Comparative effects of diazepam and buspirone on subjective feelings, psychological tests and the EEG. Int Pharmacopsychiatry 1981;16:212-20.
3. Bond A, Lader M, Shrotriya R. Comparative effects of a repeated dose regime of diazepam and buspirone on subjective ratings, psychological tests and the EEG. Eur J Clin Pharmacol 1983;24:463-7.
4. Erwin CW, Linnoila M, Hartwell J, Erwin A, Guthrie S. Effects of buspirone and diazepam, alone and in combination with alcohol, on skilled performance and evoked potentials. J Clin Psychopharmacol 1986;6:199-209.
5. Greenblatt DJ, Harmatz JS, Gouthro TA, Locke J, Shader RI. Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies. Clin Pharmacol Ther 1994;56:100-11.
6. 14C-buspirone HCl after intravenous and oral dosing in man [abstract]. Clin Pharmacol Ther 1985;37:210.
7. Kivistö KT, Lamberg TS, Kantola T, Neuvonen PJ. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther 1997;62:348-54.
8. Schlanz KD, Myre SA, Bottorff MB. Pharmacokinetic interactions with calcium channel antagonists: part I. Clin Pharmacokinet 1991;21:344-56.
9. Schlanz KD, Myre SA, Bottorff MB. Pharmacokinetic interactions with calcium channel antagonists: part II. Clin Pharmacokinet 1991;21:448-60.
10. Backman JT, Olkkola KT, Aranko K, Himberg JJ, Neuvonen PJ. Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 1994;37:221-5.
11. Varhe A, Olkkola KT, Neuvonen PJ. Diltiazem enhances the effects of triazolam by inhibiting its metabolism. Clin Pharmacol Ther 1996;59:369-75.
12. Gaillard Y, Gay-Montchamp JP, Ollagnier M. Simultaneous screening and quantitation of alpidem, zolpidem, buspirone and benzodiazepines by dual-channel gas chromatography using electron capture and nitrogen-phosphorous detection after solid-phase extraction. J Chromatogr 1993;622: 197-208.
13. Dube LM, Mousseau N, McGilveray IJ. High-performance liquid chromatographic determination of diltiazem and four of its metabolites in plasma: evaluation of their stability. J Chromatogr 1988;430:103-11.
14. Hynning PÅ, Anderson P, Bondersson U, Boreus LO. Liquid-chromatographic quantification compared with gas-chromatographic mass-spectrometric determination of verapamil and norverapamil in plasma. Clin Chem 1988;34:2502-3.
15. Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996;59:7-13.
16. Gammans RE, Mayol RF, LaBudde JA. Metabolism and disposition of buspirone. Am J Med 1986;80(suppl 3B):41-51.
17. Jajoo HK, Mayol RF, LaBudde JA, Blair IA. Metabolism of the antianxiety drug buspirone in human subjects. Drug Metab Dispos 1989;17:634-40.
18. Jajoo HK, Blair IA, Klunk LJ, Mayol RF. In vitro metabolism of the antianxiety drug buspirone as a predictor of its metabolism in vivo. Xenobiotica 1990;20:779-86.
19. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampicin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-8.
20. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Drug Metab Dispos 1994;22:947-55.
21. Kivistö KT, Bookjans G, Fromm MF, Griese EU, Münzel P, Kroemer HK. Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. Br J Clin Pharmacol 1996;42:387-9.
22. Bauer LA, Stenwall M, Horn JR, Davis R, Opheim K, Greene L. Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil and diltiazem therapy. Clin Pharmacol Ther 1986;40:239-42.